In the NIH-funded Pediatric Artificial Pancreas (PEDAP) Trial, artificial pancreas technology improved blood glucose control in young children between ages 2 and 5 with type 1 diabetes. The study was a 13-week randomized, controlled trial that enrolled 102 participants between ages 2 and 5 at three pediatric diabetes centers across the U.S. The participants were randomly assigned to either the artificial pancreas group or the standard care comparison group. The artificial pancreas, also known as closed-loop control, is a diabetes management system that tracks blood glucose levels using a continuous glucose monitor (CGM) and automatically delivers the insulin when needed using an insulin pump. The system replaces reliance on testing by fingerstick or CGM with delivery of insulin by multiple daily injections or a pump controlled by the patient or caregiver. Participants in the artificial pancreas group spent 12% more time within their target blood glucose range compared to the...

You do not currently have access to this content.